Plasma proteomics identifies four candidate biomarkers associated with macrovascular complications in type 2 diabetes: evidence from a clinical cohort and an animal model
To identify and validate plasma protein biomarkers for T2DM macrovascular complications through proteomic screening, clinical validation, and animal models. Plasma proteomics (4D-DIA, n = 6/group) was used to screen candidate proteins via differential expression, WGCNA, and PPI analyses. Candidates were vali...